San Diego, CA -- (SBWIRE) -- 01/16/2013 -- An investigation on behalf of investors of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares over potential securities laws violations by Amicus Therapeutics, Inc. and certain of its directors and officers in connection certain financial statements was announced.

Investors who purchased shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD), have certain options and should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 – 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Amicus Therapeutics, Inc. (NASDAQ:FOLD) concerning whether a series of statements by Amicus Therapeutics, Inc. (regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) reported that its annual Revenue rose from $0.92 million in 2010 to $21.43 million in 2011 and its Net Loss decreased from $54.94 million in 2010 to $44.41 million in 2011.

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) grew from $2.10 per share in Nov. 2011 to as high as $6.78 per share in February 2012. Throughout 2012 NASDAQ:FOLD shares managed to trade for the most part above $5 per share.

Then on December 19, 2012Amicus Therapeutics and GlaxoSmithKline announced the results from the first phase 3 Fabry Monotherapy study.

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) dropped from $5.97 on Dec. 18, 2012 to as low as $3.06 on Dec. 20, 2012 and continued to declined to as low as $2.53 per share on Dec. 26, 2012.

On Jan. 15, 2013, NASDAQ:FOLD shares closed at $4.19 per share.

Those who purchased shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Joelle Day
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com